An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab

Journal of the European Academy of Dermatology and Venereology

Volumn 29, Issue 4, 2015, Pages 777-782

  Amber, K T ^a   Hertl, M ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; IMMUNOLOGIC FACTOR;

ADULT; ARTICLE; DISEASE DURATION; HUMAN; IMMUNOADSORPTION; LOW DRUG DOSE; LYMPHOMA; MAJOR CLINICAL STUDY; MIDDLE AGED; PATIENT HISTORY OF THERAPY; PEMPHIGUS VULGARIS; PLASMAPHERESIS; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; PEMPHIGUS; RECURRENT DISEASE; TIME; TIME TO TREATMENT;

HUMANS; IMMUNOLOGIC FACTORS; PEMPHIGUS; PLASMA EXCHANGE; RECURRENCE; RETROSPECTIVE STUDIES; RITUXIMAB; TIME FACTORS; TIME-TO-TREATMENT;

EID: 84925460191     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12678     Document Type: Article

References (36)

1. Chams-Davatchi C, Esmaili N, Daneshpazhooh M, et al,. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol 2007; 57: 622-628.
2. Zakka LR, Shetty SS, Ahmed AR,. Rituximab in the Treatment of Pemphigus Vulgaris. Dermatol Ther (Heidelb) 2012; 2: 17.
3. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR,. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006; 355: 1772-1779.
4. Joly P, Mouquet H, Roujeau JC, et al,. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007; 357: 545-552.
5. Kim JH, Kim YH, Kim MR, Kim SC,. Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients. Br J Dermatol 2011; 165: 646-651.
6. Murrell DF, Dick S, Ahmed AR, et al,. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol 2008; 58: 1043-1046.
7. Antonucci A, Negosanti M, Tabanelli M, Varotti C,. Treatment of refractory pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab): five cases. J Dermatolog Treat 2007; 18: 178-183.
8. Arin MJ, Engert A, Krieg T, Hunzelmann N,. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol 2005; 153: 620-625.
9. Cecchi R, Gasperini U,. Severe pemphigus vulgaris treated with rituximab (Mabthera). J Dermatol 2005; 32: 862-864.
10. Cho HH, Jin SP, Chung JH,. Clinical experiences of different dosing schedules of rituximab in pemphigus with various disease severities. J Eur Acad Dermatol Venereol 2013; 28: 186-191.
11. Cianchini G, Corona R, Frezzolini A, Ruffelli M, Didona B, Puddu P,. Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature. Arch Dermatol 2007; 143: 1033-1038.
12. Colliou N, Picard D, Caillot F, et al,. Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response. Sci Transl Med 2013; 5: 175ra30.
13. Espana A, Fernandez-Galar M, Lloret P, Sanchez-Ibarrola A, Panizo C,. Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations. J Am Acad Dermatol 2004; 50: 974-976.
14. Esposito M, Capriotti E, Giunta A, Bianchi L, Chimenti S,. Long-lasting remission of pemphigus vulgaris treated with rituximab. Acta Derm Venereol 2006; 86: 87-89.
15. Goh MS, McCormack C, Dinh HV, Welsh B, Foley P, Prince HM,. Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients. Br J Dermatol 2007; 156: 990-996.
16. Herrmann G, Hunzelmann N, Engert A,. Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Br J Dermatol 2003; 148: 602-603.
17. Horvath B, Huizinga J, Pas HH, Mulder AB, Jonkman MF,. Low-dose rituximab is effective in pemphigus. Br J Dermatol 2012; 166: 405-412.
18. Kanwar AJ, Tsuruta D, Vinay K, et al,. Efficacy and safety of rituximab treatment in Indian pemphigus patients. J Eur Acad Dermatol Venereol 2013; 27: e17-e23.
19. Kasperkiewicz M, Shimanovich I, Ludwig RJ, Rose C, Zillikens D, Schmidt E,. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol 2011; 65: 552-558.
20. Leshem YA, David M, Hodak E, et al,. A prospective study on clinical response and cell-mediated immunity of pemphigus patients treated with rituximab. Arch Dermatol Res 2014; 306: 67-74.
21. Lunardon L, Tsai KJ, Propert KJ, et al,. Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. Arch Dermatol 2012; 148: 1031-1036.
22. Mamelak AJ, Eid MP, Cohen BA, Anhalt GJ,. Rituximab therapy in severe juvenile pemphigus vulgaris. Cutis 2007; 80: 335-340.
23. Marzano AV, Fanoni D, Venegoni L, Berti E, Caputo R,. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab). Dermatology 2007; 214: 310-318.
24. Menezes N, Leite I, Tente D, Couceiro A, Baptista A, Varela P,. Pemphigus vulgaris-still a difficult disease to treat. Int J Dermatol 2010; 49: 230-232.
25. Morrison LH,. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab). J Am Acad Dermatol 2004; 51: 817-819.
26. Niedermeier A, Worl P, Barth S, Schuler G, Hertl M,. Delayed response of oral pemphigus vulgaris to rituximab treatment. Eur J Dermatol 2006; 16: 266-270.
27. Reguiai Z, Tabary T, Maizieres M, Bernard P,. Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up. J Am Acad Dermatol 2012; 67: 623-629.
28. Schmidt E, Herzog S, Brocker EB, Zillikens D, Goebeler M,. Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab. Br J Dermatol 2005; 153: 449-451.
29. Shimanovich I, Nitschke M, Rose C, Grabbe J, Zillikens D,. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins. Br J Dermatol 2008; 158: 382-388.
30. Sorce M, Arico M, Bongiorno MR,. Rituximab in refractory pemphigus vulgaris. Dermatol Ther 2008; 21 (Suppl 1): S6-S9.
31. Corral IS, de Freitas TH, de Aquino RT, Koller DA, Magliari ME, Muller H,. Severe multi-resistant pemphigus vulgaris: prolonged remission with a single cycle of rituximab. An Bras Dermatol 2013; 88: 639-642.
32. Virgolini L, Marzocchi V,. Anti-CD20 monoclonal antibody (rituximab) in the treatment of autoimmune diseases. Successful result in refractory Pemphigus vulgaris: report of a case. Haematologica 2003; 88: ELT24.
33. Wenzel J, Bauer R, Bieber T, Tuting T,. Successful rituximab treatment of severe pemphigus vulgaris resistant to multiple immunosuppressants. Acta Derm Venereol 2005; 85: 185-186.
34. Kanwar AJ, Vinay K, Sawatkar GU, et al,. Clinical and immunological outcomes of high and low dose rituximab treatments in pemphigus patients: a randomized comparative observer blinded study. Br J Dermatol 2014; 170(6): 1341-9.
35. Behzad M, Mobs C, Kneisel A, et al,. Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris. Br J Dermatol 2012; 166: 844-852.
36. Pfutze M, Eming R, Kneisel A, Kuhlmann U, Hoyer J, Hertl M,. Clinical and immunological follow-up of pemphigus patients on adjuvant treatment with immunoadsorption or rituximab. Dermatology 2009; 218: 237-245.